Novel therapeutic targets on the horizon for lung cancer

Tan, Wan-Ling; Jain, Amit; Takano, Angela; Newell, Evan W.; Iyer, N. Gopalakrishna; Lim, Darren Wan-Teck; Tan, Eng‐Huat; Zhai, Weiwei; Hillmer, Axel M.; Tam, Wai Leong; Tan, Daniel S.W.

doi:10.1016/s1470-2045(16)30123-1

Cited by 161 publications

(130 citation statements)

References 140 publications

Supporting

Mentioning

129

Contrasting

Order By: Relevance

“…As these agents move quickly to treat early-stage lung cancers through clinical studies, other agents that target different aspects of the tumor-immune system milieu are being developed. Figure 2 demonstrates different strategies being utilized to enhance tumor recognition and elimination by the immune system [66]. …”

Section: Immunotherapiesmentioning

confidence: 99%

Emerging therapeutic agents for lung cancer

et al. 2016

View full text Add to dashboard Cite

Lung cancer continues to be the most common cause of cancer-related mortality worldwide. Recent advances in molecular diagnostics and immunotherapeutics have propelled the rapid development of novel treatment agents across all cancer subtypes, including lung cancer. Additionally, more pharmaceutical therapies for lung cancer have been approved by the US Food and Drug Administration in the last 5 years than in previous two decades. These drugs have ushered in a new era of lung cancer managements that have promising efficacy and safety and also provide treatment opportunities to patients who otherwise would have no conventional chemotherapy available. In this review, we summarize recent advances in lung cancer therapeutics with a specific focus on first in-human or early-phase I/II clinical trials. These drugs either offer better alternatives to drugs in their class or are a completely new class of drugs with novel mechanisms of action. We have divided our discussion into targeted agents, immunotherapies, and antibody drug conjugates for small cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC). We briefly review the emerging agents and ongoing clinical studies. We have attempted to provide the most current review on emerging therapeutic agents on horizon for lung cancer.

show abstract

Section: Immunotherapiesmentioning

confidence: 99%

Emerging therapeutic agents for lung cancer

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Non-small-cell lung cancer (NSCLC) is by far the most common type of lung cancer, making up ~85% of all diagnosed lung cancers. 1 Although intensive efforts have been devoted to developing novel combinational therapeutic options based on molecular targets for NSCLC, the outcome of patients with NSCLC remains poor due to chemoresistance. 2 Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), a member of the TNF family of ligands, is capable of initiating apoptosis by interacting with two death-inducing receptors, death receptor 4 (DR4) and death receptor 5 (DR5).…”

Section: Introductionmentioning

confidence: 99%

Gold nanoparticles enhance TRAIL sensitivity through Drp1-mediated apoptotic and autophagic mitochondrial fission in NSCLC cells

Ke¹,

Zhou²,

Yang³

et al. 2017

IJN

View full text Add to dashboard Cite

“…In 2004, the seminal discovery of activating epidermal growth factor receptor (EGFR) mutations that confer sensitivity to tyrosine kinase inhibitors (TKIs) in adenocarcinomas of NSCLCs heralded the beginning of the era of precision medicine that was based on the molecular diagnoses of NSCLCs [7,8]. In the following studies, researchers have demonstrated that besides EGFR mutations, anaplastic lymphoma kinase (ALK) rearrangements, Kirsten rat sarcoma viral oncogene (KRAS) mutations, human epidermal growth factor receptor-2 mutations and amplifications, v-Raf murine sarcoma viral oncogene homolog B mutations, rat c-ros oncogene 1 rearrangements, transfection oncogene rearrangements, encoding the proto-oncogene tyrosine kinase c-mesenchymal epithelial transition factor amplifications and exon 14 skipping serve as therapeutic targets [9,10]. According to the latest National Comprehensive Cancer Network (NCCN) guidelines (Version 2.2017), EGFR mutations and ALK rearrangements should be evaluated routinely (category 1) in patients with advanced nonsquamous NSCLCs and in patients with squamous NSCLCs that exhibit atypical clinical features (e.g.…”

Section: Introductionmentioning

confidence: 99%

Sample types applied for molecular diagnosis of therapeutic management of advanced non-small cell lung cancer in the precision medicine

Han

2017

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

Abstract:In this era of precision medicine, molecular biology is becoming increasingly significant for the diagnosis and therapeutic management of non-small cell lung cancer. The specimen as the primary element of the whole testing flow is particularly important for maintaining the accuracy of gene alteration testing. Presently, the main sample types applied in routine diagnosis are tissue and cytology biopsies. Liquid biopsies are considered as the most promising alternatives when tissue and cytology samples are not available. Each sample type possesses its own strengths and weaknesses, pertaining to the disparity of sampling, preparation and preservation procedures, the heterogeneity of inter-or intratumors, the tumor cellularity (percentage and number of tumor cells) of specimens, etc., and none of them can individually be a "one size to fit all". Therefore, in this review, we summarized the strengths and weaknesses of different sample types that are widely used in clinical practice, offered solutions to reduce the negative impact of the samples and proposed an optimized strategy for choice of samples during the entire diagnostic course. We hope to provide valuable information to laboratories for choosing optimal clinical specimens to achieve comprehensive functional genomic landscapes and formulate individually tailored treatment plans for NSCLC patients that are in advanced stages.

show abstract

Novel therapeutic targets on the horizon for lung cancer

Cited by 161 publications

References 140 publications

Emerging therapeutic agents for lung cancer

Emerging therapeutic agents for lung cancer

Gold nanoparticles enhance TRAIL sensitivity through Drp1-mediated apoptotic and autophagic mitochondrial fission in NSCLC cells

Sample types applied for molecular diagnosis of therapeutic management of advanced non-small cell lung cancer in the precision medicine

Contact Info

Product

Resources

About